Extrait

This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.

Critère d'inclusion

• Urinary Bladder, Overactive

Pays

• Australia
• Canada
• Chile
• Colombia
• Finland
• France
• Germany
• Greece
• Italy
• Latvia
• Norway
• Poland
• Slovakia
• Spain
• Switzerland
• United Kingdom

Liens

• ictrp
• nct